The FDA approved Gazyva on Sept. 25 to reduce relapse risk in patients 2 years and older with childhood-onset nephrotic syndrome. Here is what families should know.
Gazyva Wins FDA Approval for Childhood-Onset Nephrotic Syndrome, Giving Families a New Option to Reduce Relapses
by | Sep 29, 2026 | Uncategorized | 0 comments
Recent Comments